Floatz Rating
A81/100
Confidence
Indicative
Sponsor
Ritter Pharmaceuticals, Inc.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03597516CT.gov Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance | — | Completed | — | — | — |
NCT03563846CT.gov Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects | — | Completed | — | — | — |
NCT02673749CT.gov Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance | — | Completed | — | — | — |
NCT01113619CT.gov Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lactose Intolerance
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rp-G28 (this asset) | Ritter Pharmaceuticals, Inc. | P3 | A · 81 |
| Lactase | University of Pecs | P3 | BB |
| Streptococcus Thermophilus Dsm 24731 | Société des Produits Nestlé (SPN) | N/A | D |
| Lac Vaccinum | Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement | N/A | D |
| Ged (Ppargamma Modulator) | University Hospital, Lille | N/A | D |
| A2 beta-casein | Purdue University | N/A | D |
| Alverine | University of Pecs | N/A | D |
| Bifidobacterium Longum | Société des Produits Nestlé (SPN) | N/A | D |
| Simethicone | University of Pecs | N/A | D |
+1 more in the Lactose Intolerance cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rp-G28 in Lactose Intolerance. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rp-g28-lactose-intolerance
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →